Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study
The Oncologist · 04.04.2024 · 29 (4) · 303-310
DOI: 10.1093/oncolo/oyad308 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, online erschienen am 23.11.2023. Verfasst von Andrea Botticelli und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiological, Oncological and Pathological Science, Sapienza University of Rome, Rome, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Immunoconjugates, Neutropenia. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Trastuzumab deruxtecan (T-DXd) demonstrated unprecedented efficacy in patients with pretreated HER2+ metastatic breast cancer (mBC). However, few data are available about its efficacy in routine clinical practice. In this multicenter retrospective study, we examined effectiveness and safety of T-DXd in a real-world population.
Methods
Clinico-pathological information about patients with HER2+ mBC who received T-DXd were collected from 12 Italian hospitals. HER2 status was determined locally. Patients who received at least one administration of T-DXd, as any therapy line for advanced disease were included in the analysis. The primary endpoint was real-word PFS (rwPFS).
Results
One hundred and forty-three patients were included. Median age was 66 (range: 37-90), and 4 men were included. Hormone receptor (HR) status was positive in 108 (75%) patients and negative in 35(25%). T-DXd was administered as first, second, third, or subsequent lines in 4 (3%), 16 (11%), 42 (29%), and 81 (57%) patients, respectively. Among 123 patients with measurable disease, the ORR was 68%, and the DCR was 93% (9 CRs, 74 PRs, and 30 SD). Nine (7%) patients had a primary resistance to T-DXd. With a median follow-up of 12 months, the median rwPFS was 16 months. RwPFS was 84%, 59%, and 39% at 6, 12, and 18 months, respectively. A favorable trend in rwPFS was reported in patients receiving T-DXd as I/II line versus further lines (17 vs. 15 months; P = .098). Any-grade toxicity was registered in 84 patients (59%). Most common adverse events (AEs) reported were nausea (33%), neutropenia (21%), and asthenia (21%). Liver toxicity and diarrhea were uncommon (5% and 1%). Severe toxicities was registered in 18% of patients, and the most frequent were neutropenia, nausea/vomiting, and ILD observed in 15, 2, and 3 patients. AEs led to dose reduction in 37 patients (26%). Dose reduction and AEs do not affect patients’ response and survival outcomes.
Conclusions
Efficacy and safety of T-DXd were confirmed in an unselected real-world population of HER2+ mBC. These results are consistent with the results of known findings, and no new safety concerns were reported.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiological, Oncological and Pathological Science, Sapienza University of Rome, Rome, Italy.
- Department of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Pascale, Naples, Italy.
- Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
- Department of Oncology and Hematology, University of Milan, Milan, Italy.
- Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.
- Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.
ORCID-Profile: Andrea Botticelli, Simone Scagnoli, Giuseppe Curigliano, Matteo Lambertini
Zitieren
APA
Botticelli, A., Caputo, R., Scagnoli, S., Pisegna, S., De Laurentiis, M., Curigliano, G., Lambertini, M., Pantano, F., Palazzo, A., Paris, I., Vernieri, C., Tedesco, B., Giampaglia, M., Palleschi, M., Ballatore, Z., Alesini, D., D'Auria, G., Fabbri, A., Rossi, L., …, & Fabi, A. (2024). Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study. The Oncologist, 29(4), 303-310. https://doi.org/10.1093/oncolo/oyad308
Vancouver
Botticelli A, Caputo R, Scagnoli S, Pisegna S, De Laurentiis M, Curigliano G, et al. Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study. The Oncologist. 2024;29(4):303-310. doi:10.1093/oncolo/oyad308
BibTeX
@article{Botticelli2024,
author = {Botticelli, Andrea and Caputo, Roberta and Scagnoli, Simone and Pisegna, Simona and De Laurentiis, Michelino and Curigliano, Giuseppe and Lambertini, Matteo and Pantano, Francesco and Palazzo, Antonella and Paris, Ida and Vernieri, Claudio and Tedesco, Beatrice and Giampaglia, Marianna and Palleschi, Michela and Ballatore, Zelmira and Alesini, Daniele and D'Auria, Giuliana and Fabbri, Agnese and Rossi, Luigi and Verrazzo, Annarita and Scafetta, Roberta and Marinelli, Daniele and Sposetti, Caterina and Barberi, Vittoria and Strigari, Lidia and Marchetti, Paolo and Santini, Daniele and Fabi, Alessandra},
title = {Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study},
journal = {The Oncologist},
year = {2024},
volume = {29},
number = {4},
pages = {303--310},
doi = {10.1093/oncolo/oyad308}
}
EUVIMED